A review of heart failure treatment

Mount Sinai Journal of Medicine

Volumn 71, Issue 1, 2004, Pages 47-54

  Guyatt, Gordon H ^a   Devereaux, Philip J ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Anti arrhythmic agents; Anticoagulation; Beta blockers; Digitalis; Exercise; Heart failure; Randomized controlled trials; Ventricular assist device

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DIGITALIS; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISOPYRAMIDE; DIURETIC AGENT; ENALAPRIL; ENCAINIDE; FLECAINIDE; HYDRALAZINE; LISINOPRIL; LOOP DIURETIC AGENT; METOLAZONE; MEXILETINE; MORACIZINE; NITRIC ACID DERIVATIVE; PLACEBO; PROCAINAMIDE; QUINIDINE; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VASODILATOR AGENT; WARFARIN;

BRADYCARDIA; CLINICAL TRIAL; COUGHING; DEVELOPED COUNTRY; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL HEMORRHAGE; HEART FAILURE; HEART TRANSPLANTATION; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOCHLOREMIA; HYPOKALEMIA; HYPONATREMIA; ISCHEMIC HEART DISEASE; META ANALYSIS; MORTALITY; PATIENT MONITORING; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; STROKE; SYMPTOMATOLOGY; THROMBOEMBOLISM;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; DIURETICS; HEART FAILURE, CONGESTIVE; HUMANS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; VASODILATOR AGENTS;

EID: 0742324164     PISSN: 00272507     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Guyatt GH. Evidence-based medicine [editorial]. ACP Journal Club 1991:A-16. (Ann Intern Med 114 Suppl 2).
2. Cowie MR, Mosterd A, Wood DA, et al. The epidemiology of heart failure. Eur Heart J 1997; 18:208-225.
3. Ho KKI, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham study. J Am Coll Cardiol 1993; 22(Suppl A):6A-13A.
4. Adams KF Jr, Zannand F. Clinical definition and epidemiology of advanced heart failure. Am Heart J 1998; 135:S204-S215.
5. Kannel WB, Ho K, Thom T. Changing epidemiological features of cardiac failure. Br Heart J 1994; 72(2 Suppl):S3-S9.
6. Teerlink JR, Goldhaber SZ, Pfeffer MA. An overview of contemporary etiologies of congestive heart failure. Am Heart J 1991; 121:1852-1853.
7. Schulman KA, Buxton M, Glick H, et al. Results of the economic evaluation of the first study. A multinational prospective economic evaluation. FIRST Investigators. Flolan International Randomized Survival Trial. Int J Technol Assess Health Care 1996;12(4):698-713.
8. Harlan WR, Obermann A, Grimm R, Rosati RA. Chronic congestive heart failure in coronary artery disease: clinical criteria. Ann Intern Med 1977; 86:133-138.
9. Wheeldon NM, MacDonald TM, Flucker CJ, et al. Echocardiography in chronic heart failure in the community. Q J Med 1993; 86:17-23.
10. Reines J, Reunanen A, Aromaa A, Pyorala K. Incidence of heart failure in eastern Finland: a population-based surveillance study. Eur Heart J 1992; 13:588-593.
11. Tresch DD. The clinical diagnosis of heart failure in older patients. J Am Geriatr Soc 1997; 45:1128-1133.
12. Cleland JGF, Habib F. Assessment and diagnosis of heart failure. J Intern Med 1996; 239:317-325.
13. Krishnaswamy P, Lubien E, Clopton P, et al. Utility of B-natriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction. Am J Med 2001; 111:274-279.
14. Goldman L, Hashimoto B, Cook EF, Loscalzo A. Comparative reproducibility and validity of systems for assessing cardiovascular functional class: advantages of a new specific activity scale. Circulation 1981; 64:1227-1234.
15. Senni M, Tribouilloy CM, Rodeheffer RJ, et al. Congestive heart failure in the community. Arch Intern Med 1999; 159:29-34.
16. Kalon KLH, Keaven MA, Kannel WB, et al. Survival after the onset of congestive heart failure in Framingham heart subjects. Circulation 1993; 88:107-115.
17. Jong P, Vowinckel E, Liu PP, et al. Prognosis and determinants of survival in patients newly hospitalized for heart failure: a population-based study. Arch Intern Med 2002; 162:1689-1694
18. Guyatt G, Cook D, Devereaux PJ, et al. Therapy. In: Guyatt G, Rennie D. The users' guides to the medical literature: a manual for evidence-based clinical practice. Chicago (IL): AMA publications; 2002. pp. 55-79.
19. Oxman A, Guyatt G, Cook D, Montori V. Summarizing the evidence. In: Guyatt G, Rennie D. The users' guides to the medical literature: a manual for evidence-based clinical practice. Chicago (IL): AMA publications; 2002. pp. 155-173.
20. Montori V, Hatala R, Guyatt G. Evaluating differences in study results. In: Guyatt G, Rennie D. The users' guides to the medical literature: a manual for evidence-based clinical practice. Chicago (IL): AMA publications; 2002. pp. 549-552.
21. Jaeschke R, Guyatt G, Barratt A, et al. Measures of association. In: Guyatt G, Rennie D. The users' guides to the medical literature: a manual for evidence-based clinical practice. Chicago (IL): AMA publications; 2002. pp. 351-368.
22. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1996; 273:1450-1456.
23. Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000; 355:1575-1581.
24. Visser FC, Visser CA. Current controversies with ACE inhibitor treatment in heart failure. Cardiology 1996; 87:23-28.
25. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999; 100:2312-2318.
26. Jong P, Demers C, McKelvie RS, Liu PP. Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials. J Am Coll Cardiol 2002; 39:463-470.
27. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986; 314:1547-1552.
28. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325:303-310.
29. Brater DC. Diuretic therapy. N Engl J Med 1998; 339:387-395.
30. Konstan MA, Remme WJ. Treatment guidelines in heart failure. Prog Cardiovasc Dis 1998; 41:65-72.
31. Stevenson LW, Massie BM, Francis GS. Optimizing therapy for complex or refractory heart failure: a management algorithm. Am Heart 1998; 135(6 Pt 2 Su):S293-S309.
32. Dormans TPJ, Gerlag PGG, Russel FGM, Smits P. Combination diuretic therapy in severe congestive heart failure. Drugs 1998; 55:165-172.
33. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336:525-533.
34. Jaeschke R, Oxman AD, Guyatt GH. To what extent do congestive heart failure patients in sinus rhythm benefit from digoxin therapy? A systematic review and meta-analysis. Am J Med 1990; 88:279-286.
35. Packer M, Gheorghiade M, Young JB, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. N Engl J Med 1993; 329:1-7.
36. Uretsky BF, Young JB, Shahidi FE, et al. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure. J Am Coll Cardiol 1993; 22:955-962.
37. Cleland JG, Thygesen K, Uretsky BF, et al. ATLAS investigators. Cardiovascular critical event pathways for the progression of heart failure: a report from the ATLAS study. Eur Heart J 2001; 22:1601-1612.
38. Zarembski DG, Nolan PE, Slack MK, Lui CY. Meta-analysis of the use of low-dose beta-adrenergic blocking therapy in idiopathic or ischemic dilated cardiomyopathy. Am J Cardiol 1996; 77:1247-1250.
39. Doughty RN, Rodgers A, Sharpe N, MacMahon S. Effects of beta-blocker therapy on mortality in patients with heart failure. Eur Heart J 1997; 18:560-565.
40. Heidenreich PA, Lee TT, Massie BM. Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 1997; 30:27-34.
41. Avezum A, Tsuyuki RT, Pogue J, Yusuf S. Beta-blocker therapy for congestive heart failure: a systematic overview and critical appraisal of the published trials. Can J Cardiol 1998; 14:1045-1053.
42. Lechat P, Packer M, Chalon S, et al. Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation 1998; 98:1184-1191.
43. Brophy JM, Joseph L, Rouleau JL. Beta-blockers in congestive heart failure. A Bayesian meta-analysis. Ann Intern Med 2001; 134:550-560.
44. Bonet S, Agusti A, Arnau JM, et al. Beta-adrenergic blocking agents in heart failure: benefits of vasodilating and non-vasodilating agents according to patients' characteristics: a meta-analysis of clinical trials. Arch Intern Med 2000; 160:621-627
45. Kannel WB, Plehn JF, Cupples LA. Cardiac failure and sudden death in the Framingham study. Am Heart J 1988; 115:869-875.
46. Bigger JT Jr. Why patients with congestive heart failure die: arrhythmias and sudden cardiac death. Circulation 1987; 75(5 Pt 2):IV28-IV35.
47. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide or placebo: the Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324:781-788.
48. The Cardiac Arrhythmia Suppression Trial II Investigators. Effect of antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992; 327:227-233.
49. Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. JAMA 1993; 270:1589-1595.
50. Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Lancet 1997; 350:1417-1424.
51. Laupacis A, Boysen G, Connolly S, et al. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Arch Intern Med 1994; 1554:1449-1457.
52. Levine MN, Raskob G, Landefeld S, Keaton C. Hemorrhagic complications of anticoagulant therapy. Chest 2001; 119(1 Suppl):108S-121S.
53. Koniaris LS, Goldhaber SZ. Anticoagulation in dilated cardiomyopathy. J Am Coll Cardiol 1998; 31:745-748.
54. Tsevat J, Eckman MH, McNutt RA, Pauker SG. Warfarin for dilated cardiomyopathy: a bloody tough pill to swallow? Med Decis Making 1989; 9:162-169.
55. Louis AA, Manousous IR, Coletta AP, et al. Clinical trials update: The Heart Protection Study, IONA, CARISA, ENRICHD, ACUTE, ALIVE, MADIT II, and REMATCH. Eur J Heart Fail 2002; 4:111-116.
56. Lloyd-Williams F, Mair FS, Leitner M. Exercise training and heart failure: a systematic review of current evidence. Br J Gen Practice 2002; 52:47-55.
57. McAlister FA, Lawson FM, Teo KK, Armstrong PW. A systematic review of randomized trials of disease management programs in heart failure. Am J Med 2001; 110:378-384.
58. Blue L, Lang E, McMurray JJ, et al. Randomised controlled trial of specialist nurse intervention in heart failure. BMJ 2001; 323:715-718.
59. Roter DL, Hall JA, Merisca R, et al. Effectiveness of interventions to improve patient compliance: a meta-analysis. Med Care 1998; 36:1138-1161.
60. Guyatt GH, Sackett DL, Taylor DW, et al. Determining optimal therapy - randomized trials in individual patients. N Engl J Med 1986; 314:889-892.
61. Guyatt GH, Sackett DL, Adachi JD, et al. A clinician's guide for conducting randomized trials in individual patients. Can Med Ass J 1988; 139:497-503.
62. Packer M, O'Connor CM, Ghali JK, et al. Effect of amlodopine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996; 335:1107-1114.